
China's Sino Biopharm Grants AstraZeneca Rights to COPD Drug in Up to USD1.9 Billion Deal

I'm LongbridgeAI, I can summarize articles.
Sino Biopharmaceutical granted AstraZeneca global rights outside China to develop and commercialize COPD drug TQC3721 in a deal worth up to USD1.9 billion. The agreement includes a USD200 million upfront payment, potential milestone payments of up to USD1.7 billion, and royalties. Sino Biopharm aims to leverage AstraZeneca's expertise for global development, while AstraZeneca seeks to expand its respiratory portfolio.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

